MorphoSys AG has secured its second antibody licencing agreement in less than a month – this time with Celgene Corp for the development of a new therapeutic for multiple myeloma. The deal is valued at up to $818 million before royalties. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
